Cutera Inc. (NASDAQ:CUTR) CEO Ronald J. Santilli sold 53,346 shares of the firm’s stock in a transaction dated Monday, November 14th. The stock was sold at an average price of $14.05, for a total transaction of $749,511.30. Following the completion of the transaction, the chief executive officer now directly owns 125,958 shares in the company, valued at approximately $1,769,709.90. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Cutera Inc. (NASDAQ:CUTR) opened at 14.30 on Thursday. The firm has a 50-day moving average of $13.42 and a 200-day moving average of $11.55. Cutera Inc. has a one year low of $9.83 and a one year high of $14.94. The company has a market cap of $191.73 million, a PE ratio of 446.87 and a beta of 0.74.

Cutera (NASDAQ:CUTR) last released its quarterly earnings data on Monday, November 7th. The medical device company reported $0.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.04 by $0.08. The business earned $30.30 million during the quarter, compared to analyst estimates of $28.84 million. Cutera had a net margin of 0.38% and a return on equity of 4.82%. Cutera’s quarterly revenue was up 31.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.07) EPS. On average, analysts predict that Cutera Inc. will post $0.23 EPS for the current year.

Separately, Zacks Investment Research cut shares of Cutera from a “buy” rating to a “hold” rating in a report on Wednesday, November 9th.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Renaissance Technologies LLC raised its position in Cutera by 8.2% in the first quarter. Renaissance Technologies LLC now owns 1,074,900 shares of the medical device company’s stock worth $12,093,000 after buying an additional 81,069 shares in the last quarter. Lyon Street Capital LLC raised its position in Cutera by 0.4% in the second quarter. Lyon Street Capital LLC now owns 645,814 shares of the medical device company’s stock worth $7,240,000 after buying an additional 2,550 shares in the last quarter. BlackRock Institutional Trust Company N.A. raised its position in Cutera by 2.3% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 623,300 shares of the medical device company’s stock worth $7,430,000 after buying an additional 13,773 shares in the last quarter. Vanguard Group Inc. raised its position in Cutera by 0.8% in the second quarter. Vanguard Group Inc. now owns 555,088 shares of the medical device company’s stock worth $6,223,000 after buying an additional 4,266 shares in the last quarter. Finally, Stonepine Capital Management LLC raised its position in Cutera by 17.6% in the second quarter. Stonepine Capital Management LLC now owns 438,000 shares of the medical device company’s stock worth $4,910,000 after buying an additional 65,700 shares in the last quarter. 79.41% of the stock is owned by hedge funds and other institutional investors.

About Cutera

Cutera, Inc is a medical device company. The Company is engaged in the design, development, manufacture, marketing and servicing of laser and other energy-based aesthetics systems for practitioners across the world. The Company offers products based on product platforms, such as enlighten, excel HR, truSculpt, excel V and xeo, each of which enables physicians and other practitioners to perform aesthetic procedures for customers.

5 Day Chart for NASDAQ:CUTR

Receive News & Stock Ratings for Cutera Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cutera Inc. and related stocks with our FREE daily email newsletter.